Skip to main content
PROF logo

PROF · Profound Medical Corp.

Track PROF — free
$6.63 -0.04 (-0.60%) At close · Aug 14
Market Cap
$242.21M
Shares
36.53M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.63 Open$6.64 Day$6.55–6.80 52W close$3.87–8.65 Avg vol 30d119K Short int1.8M · 4.9% float · 14.7d Short vol83% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Oct 22, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −3%
      below
      Price vs 50-day avg −5%
      below
      RSI (14) 39
      neutral
      MACD trend Negative
      52-week position 58%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return −3%
      trailing
      6-month return −7%
      trailing
      YTD return −16%
      this year
      Relative strength −21%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 50d above 200d
      Institutional flow Distributing
      -2% holders QoQ · +7 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.94% of float · ▼ -2.6% MoM · 14.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      57 holders — mid 3-yr range
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +51%
      Y/Y
      Gross margin 71%
      expanding
      EPS growth +26%
      Y/Y
      Free cash flow $-38.4M
      Balance sheet $53.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 74%
      annualized · 1-yr
      Max drawdown −42%
      past year
      ATR 6.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      full-year 2026
      Total revenue $25M
      full year 2026
      Gross margin at least 70%
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2024
      Revenue · full year 2024 $11M – $12M
      Gross margin · full year 2024 at least 60%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      2 · 4 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −3% Neutral
      Price vs 50-day avg
      −5% Bearish
      RSI (14)
      39 Neutral
      MACD trend
      Negative Bearish
      52-week position
      58% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 50d above 200d
      Institutional flow Distributing
      -2% holders QoQ · +7 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.94% of float · ▼ -2.6% MoM · 14.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      57 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $4 Now $7 · 58% Range high $9
      vs 200-day avg -3% vs 50-day avg -5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Payer coverage expanded 18.3M Q2-2026
      Covered lives added (total, including Humana) 8.5M Q1-2026
      Humana covered lives 6.9M Q1-2026
      TULSA-PRO installed base 80 Q1-2026

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PROF
      Profound Medical Corp.
      this stock
      $242.21M -15.8% +50.7% 4.9%
      ABT
      Abbott Laboratories
      $193.78B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      $130.11B -3.5% +11.2% 35.2 2.2%
      MDT
      Medtronic plc
      $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      $75.11B -45.6% +12.5% 21.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      57
      % held
      43.6%
      Net QoQ
      -494.0K sh
      Top holder
      FIL Ltd
      Held Float
      View
      Held by Funds
      Fund positions
      9
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.8M
      Days to cover
      14.7d
      Change
      -47.4K sh
      View
      Short Volume
      Short vol %
      83%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7.7K
      Value
      $56.2K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      42.7%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Tom Malinowski
      Amount
      $1.0K–$15.0K
      Traded
      Jul 21, 2020
      View
      Financials
      Financials
      Revenue (FY)
      $16.1M
      Net income (FY)
      $-42.6M
      EPS diluted
      $1.41
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      26
      View
      Proposed Sales
      Value
      $105.5K
      Shares
      13.0K
      Filed
      Nov 12, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PROF -10.5% -3.2% -7.3% -10.2% -15.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -10.9% -7.7% -21.0% -14.1% -29.6%
      Key facts CIK 1628808 CUSIP 74319B502 13F (30d) 56 filings 56 filers Visit website Investor relations